Increased Expression of TGFβR2 Is Associated with the Clinical Outcome of Non-Small Cell Lung Cancer Patients Treated with Chemotherapy

Yang Han; Chengyou Jia; Xianling Cong; Fei Yu; Haidong Cai; Suyun Fang; Li Cai; Huiqiong Yang; Yu Sun; Dan Li; Jin Liu; Ruting Xie; Xueyu Yuan; Xiaoming Zhong; Ming Li; Qing Wei; Zhongwei Lv; Da Fu; Yushui Ma

doi:10.1371/journal.pone.0134682

Increased Expression of TGFβR2 Is Associated with the Clinical Outcome of Non-Small Cell Lung Cancer Patients Treated with Chemotherapy

PLoS One. 2015 Aug 7;10(8):e0134682. doi: 10.1371/journal.pone.0134682. eCollection 2015.

Authors

Yang Han¹, Chengyou Jia¹, Xianling Cong², Fei Yu¹, Haidong Cai¹, Suyun Fang¹, Li Cai¹, Huiqiong Yang¹, Yu Sun¹, Dan Li¹, Jin Liu¹, Ruting Xie³, Xueyu Yuan¹, Xiaoming Zhong⁴, Ming Li⁵, Qing Wei³, Zhongwei Lv¹, Da Fu¹, Yushui Ma¹

Affiliations

¹ Department of Nuclear Medicine, Shanghai 10th People's Hospital, Tongji University School of Medicine, Shanghai, China.
² Tissue Bank, China-Japan Union Hospital, Jilin University, Changchun, China.
³ Department of pathology, Shanghai 10th People's Hospital, Tongji University School of Medicine, Shanghai, China.
⁴ Department of Radiology, Jiangxi Provincial Tumor Hospital, Nanchang, China.
⁵ Department of Respiratory Medicine, Shanghai 10th People's Hospital, Tongji University School of Medicine, Shanghai, China.

Abstract

To investigate the prognostic significance of TGFβR2 expression and chemotherapy in Chinese non-small cell lung cancer (NSCLC) patients, TGFβR2 expression NSCLC was analyzed in silico using the Oncomine database, and subsequently analyzed with quantitative RT-PCR in 308 NSCLC biopsies, 42 of which were paired with adjacent non-neoplastic tissues. Our results show that TGFβR2 expression was also increased in NSCLC biopsies relative to normal tissue samples and correlated with poor prognosis. TGFβR2 expression was also significantly correlated with other clinical parameters such as tumor differentiation, invasion of lung membrane, and chemotherapy. Moreover, overall survival (OS) and disease free survival (DFS) was increased in patients with low TGFβR2 expressing NSCLC and who had undergone chemotherapy. Thus, high expression of TGFβR2 is a significant risk factor for decreased OS and DFS in NSCLC patients. Thus, TGFβR2 is a potential prognostic tumor biomarker for chemotherapy.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers, Tumor / metabolism
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics*
Disease-Free Survival
Female
Gene Expression Regulation, Neoplastic
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics*
Middle Aged
Prognosis
Proportional Hazards Models
Protein Serine-Threonine Kinases / genetics*
Protein Serine-Threonine Kinases / metabolism
Receptor, Transforming Growth Factor-beta Type II
Receptors, Transforming Growth Factor beta / genetics*
Receptors, Transforming Growth Factor beta / metabolism
Survival Analysis
Treatment Outcome

Substances

Biomarkers, Tumor
Receptors, Transforming Growth Factor beta
Protein Serine-Threonine Kinases
Receptor, Transforming Growth Factor-beta Type II

Grants and funding

This study was supported partly by grants from the National Natural Science Foundation of China (81371595, 81372175, 81301993, 81472501, 81201535, 81472202 and 81302065), Nature Science Foundation of Shanghai (12ZR1436000), Shanghai Municipal Science and Technology Commission (14441901300, 14DZ1940606), Shanghai Municipal Commission of Health and Family Planning (XBR2013112, 2013SY036) and Youth Innovation Promotion Association, Chinese Academy of Sciences (Y219J11311).